REFERENCES
- Shankar AG. The role of recombinant erythropoietin in childhood cancer. Oncologist. 2008;13(2):157–166.
- Blumer J, Berg S, Adamson PC, Pharmacokinetic evaluation of darbepoetin alfa for the treatment of pediatric patients with chemotherapy-induced anemia. Pediatr Blood Cancer. 2007;49(5):687–693.
- Wauters I, Pat K, Vansteenkiste J. Flexible dosing with darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ther Clin Risk Manag. 2006;2(2):175–186.
- Wauters I, Vansteenkiste J. Darbepoetin alfa in the treatment of chemotherapy-induced anaemia. Expert Opin Biol Ther. 2009;9(2):221–230.
- Yoshioka E, Kato K, Shindo H, Pharmacokinetic study of darbepoetin alfa: absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats. Xenobiotica. 2007;37(1):74–90.
- Corazza FV. Physiopathologic aspects of anemia and thrombocytopenia in children with cancers: the roles of erythropoietin and thrombopoietin [Abstarct]. Bull Mem Acad R Med Belg. 2008;163(1–2):152–156.
- Dowd MD, Morgan ER, Langman CB, Murphy S. Serum erythropoietin levels in children with leukemia. Med Pediatr Oncol. 1997;28(4):259–267.
- Miller CB, Jones RJ, Piantadosi S, Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med. 1990;322(24):1689–1692.
- Ozguroglu M, Arun B, Demir G, Serum erythropoietin level in anemic cancer patients. Med Oncol. 2000;17(1):29–34.
- Abdelrazik N, Fouda M. Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. Hematology. 2007;12(6):533–541.
- Glaspy JA, Jadeja JS, Justice G, A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003;97(5):1312–1320.
- Schwartzberg L, Burkes R, Mirtsching B, Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. BMC Cancer. 2010;10:581.
- Smith RE Jr, Tchekmedyian NS, Chan D, A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer. Br J Cancer. 2003;88(12):1851–1858.
- Glaspy J, Henry D, Patel R, Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005;41(8):1140–1149.
- Nordstrom BL, Luo W, Fraeman K, Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter. J Manag Care Pharm. 2008;14(9):858–869.
- Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost. 2007;33(4):355–364.
- Rizzo JD, Somerfield MR, Hagerty KL, Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood. 2008;111(1):25–41.
- Rizzo JD, Brouwers M, Hurley P, American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract. 2010;6(6):317–320.
- Rizzo JD, Brouwers M, Hurley P, American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116(20):4045–4059.
- Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: a review of evidence for improved quality of life and clinical outcomes. Ann Oncol. 2003;14(4):511–519.
- Boccia R, Lillie T, Tomita D, Balducci L. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia. Oncologist. 2007;12(5):584–593.
- Barosi G, Marchetti M, Liberato N. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. Br J Cancer. 1998;78:781–787.
- Wilson J, Yao GL, Raftery J, A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess. 2007;11(13):1–202, iii–iv.